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 Abstract 
Aims/Hypothesis 
To determine the association between inpatient glycemic variability and long-term 
mortality in patients with type 2 diabetes mellitus.  
 
Methods  
Capillary blood glucose (CBG) of inpatients from 8 hospitals was analysed. 28,353 
admissions identified were matched for age, duration of diabetes and admission and 
median and interquartile range of CBG. 6 year mortality was investigated for (i) those 
with CBG IQR in the top half of all IQR measurements (matched for all except IQR), 
vs those in the lower half and (ii) those with the lowest quartile median glucose 
(matched for all except median). 
 
Results 
1. Glycemic variability 
3165 matched pairs analysed. Mortality was greater in those with IQR in upper 50% 
(>=50.9 mg/dl) over follow-up from day 90 post-discharge to a maximum of 6 years 
(p <0.01, HR 1.17). 
2. Median glucose  
3755 matched pairs analysed. Mortality was lower in those with a median glucose in 
upper 50% (>=148.5 mg/dl) over follow-up from day 90 post-discharge to a 
maximum of 6 years (p <0.01, HR 0.87). 
 
Conclusion  
Higher inpatient glycemic variability is associated with increased mortality on long-
term follow up. When matched by IQR, we have demonstrated higher median CBG is 
associated with lower long term mortality. CBG variability may increase 
cardiovascular morbidity by increasing exposure to hypoglycaemia or to variability 
per se. In hospitalized patients with diabetes, glycemic variability should be 
minimised and when greater CBG variability is unavoidable, a less stringent CBG 
target considered. 
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Introduction  
Diabetes mellitus is an increasingly common and important condition worldwide, 
with an estimated growth to 366 million diagnoses by 2030. (1) With this increasing 
burden of disease worldwide, the importance of optimal management of diabetes will 
be a progressively greater challenge over the coming years. There is definitive 
evidence of deleterious effects of hyperglycaemia on long-term patient outcomes, 
with increased risks of both micro and macrovascular complications of diabetes. 
(2,3,4,5) This association led to an emphasis on tight glycemic control. A major side-
effect of this approach however, is an increased prominence of hypoglycaemia. (6) 
Hypoglycaemia triggers activation of counterregulatory hormonal systems and is 
associated with multiple negative effects, including cardiovascular events and death. 
(7,8,9,10). More recently, there has been interest in whether fluctuations in glucose 
are important over and above low and high absolute levels, with increasing evidence 
to suggest that high glycemic variability is associated with negative outcomes. (11) 
 Amongst hospitalized patients, patients with diabetes mellitus are over represented 
and may account for up to 25% of an inpatient population despite accounting for only 
5-8% of the general population. (12) While complications of glycemic control may 
lead to admission to hospital in these patients, admission is often for other medical or 
surgical conditions. Aside from the pathology leading to admission to hospital, the 
management of pre-existing diabetes must be an important consideration in optimal 
holistic patient management. It has previously been unequivocally demonstrated that 
length of hospital stay and mortality is increased in patients with diabetes. (12,13,14) 
This is perhaps due in part to suboptimal management of underlying diabetes. 
Intercurrent illness in itself, can also destabilise diabetic control making the 
achievement of optimal glycaemia even more challenging in the inpatient setting. (13) 
 
The importance of hyperglycemia and hypoglycemia have been extensively explored 
within a hospital setting, but there has been less scrutiny of glycemic variability as an 
independent marker of poor outcome. (11) There is evidence that the variability of 
blood glucose has a bearing on the incidence of microvascular and macrovascular 
diabetic complications. (15,16) There has also been some evidence which suggests 
increased mortality associated with increased glycemic variability. (17) 
 
Despite the increased interest in glycemic variability in recent years, and the 
increasing evidence of its negative impact, there are few large scale studies examining 
the effect of high glycemic variability on long-term outcome and mortality. Limited 
evidence is available of whether the negative effects identified in vitro translate into 
patient outcomes. Moreover, there is little evidence as to what glycemic target should 
be set in hospital inpatients, so as to mitigate any risk associated with high glycemic 
variability.  
 This study sought to test the hypothesis that high glycemic variability as a hospital 
inpatient, is independently associated with increased mortality on long-term follow 
up.  
 
Methods  
Data management. All inpatients who underwent capillary blood glucose (CBG) 
monitoring within the Greater Glasgow and Clyde NHS health board (NHS GGC) 
area between January 2009 and January 2015 were included in an initial acquisition of 
data. Data was drawn from the Abbott Precision Web glucose monitoring system used 
throughout NHS GGC. Quality control of this system has local oversight from the 
clinical laboratory service, with external oversight being provided by national 
reference laboratories. 
This inpatient CBG dataset was merged with a national diabetes register (SCI 
Diabetes) - which contains information on all patients with a coded diagnosis of 
diabetes within Scotland - to obtain a data subset comprising all patients with diabetes 
mellitus in whom CBG values were monitored during the period of interest. Analysis 
was performed on those individuals with a recorded diagnosis of type 2 diabetes only. 
A single admission for each individual was analysed. The first chronological 
admission in the dataset where there were 4 or more recorded CBG values (to allow 
meaningful calculation of glucose excursion metrics) for each individual was 
analysed. Mortality data from SCI Diabetes (ultimately drawn from the national 
Information Services Division (NHS Scotland) mortality dataset) were linked to the 
CBG dataset. As far as can be ascertained, this dataset is complete (with the exception 
of individuals who may have left Scotland during the period of study). 
Age was calculated from the unique patient identification (CHI) number, which 
contains within it the date of birth. Duration of diabetes was calculated from the date 
of admission and the date of diagnosis contained within the SCI Diabetes dataset. 
Duration of admission was calculated from the CBG data, taking the time of the first 
CBG measurement as the time of admission, and the time of the last contiguous CBG 
where the time between CBG measures is less than 5 days, as the time of discharge. 
Median and interquartile range (IQR) of inpatient CBG values were calculated for 
each admission. Biochemical episodes of hypoglycaemia were calculated for each 
admission, with an episode of hypoglycaemia defined as a contiguous series of CBG 
measures <72 mg/dl where the time interval between each measure was <60 minutes. 
Case/control identification and matching. Cases were selected according to the 
analysis being performed. To investigate the association between glucose variability 
and survival, cases - those with a CBG IQR within the upper 50% of all IQR values - 
were matched with controls . Controls for each case were drawn from the set with 
IQR values within the lower 50% of all IQR values. Controls were additionally 
matched using the variables of of age (+/- 5 years), duration of diabetes (+/- 5 years), 
duration of admission (+/- 0.5 days), median CBG during admission (+/- 2.25 mg/dl) 
and number of episodes of hypoglycaemia. Where the median CBG was the metric 
under test, cases were drawn from admissions with a median CBG within the upper 
50% of median CBG values, with controls drawn from the lower 50%. As above, 
controls were matched using age, duration of diabetes, duration of admission and 
number of episodes of hypoglycaemia. In this analysis, matching included the CBG 
IQR (+/- 2.25 mg/dl). Where multiple matched controls were identified, a match was 
selected from the available pool of controls at random. A unique control was used for 
each case (controls were not reused). Survival over a maximum 6 year follow up 
period was examined using survival analysis and cox proportional hazards model, 
with the parameter under investigation as a covariate. 
Early mortality. The confounding effect of inpatient and early post-discharge 
mortality was considered to be potentially significant. Analyses investigating survival 
from the point of discharge, 30, 60 and 90 days post-discharge to the end of the the 
follow up period were examined. Analyses including time points earlier than 90 days 
post-discharge demonstrated a continuously changing gradient of the survival curve - 
thought to represent the effect of elevated mortality associated with the acute 
admission. Given the assumption of a constant relative hazard inherent within the cox 
model, it was important to begin the survival analysis after this ‘early’ mortality effect 
had diminished, and 90 days post-discharge was therefore chosen as the start point for 
the survival analysis. 
 
Results  
Data associated with 28,353 unique individuals with diabetes mellitus, who had had 
one or more admissions were identified. 24,181 individuals had a coded diagnosis of 
type 2 diabetes mellitus. 
 
Glucose variability analysis: 3165 matched pairs were identified. A table of 
comparative values for each of the matching parameters for case and control groups is 
shown in Table 1. 
Higher inpatient glycemic variability was demonstrated to be associated with 
decreased survival from day 90 post-discharge over follow up for a 6 year period 
(p<0.01) (figure 1). Hazard Ratio for mortality was 1.17 in the higher variability 
group. Table of demographics and matching parameters for case and control groups is 
shown in Table 1. 
 Median CBG analysis: 3755 matched pairs were identified. A table of comparative 
values for each of the matching parameters for case and control groups is shown in 
Table 2. 
Higher inpatient median CBG was demonstrated to be associated with increased 
survival from day 90 post-discharge over follow up for a 6 year period (p<0.01) 
(figure 2). Hazard Ratio for mortality was 0.87 in the higher variability group. Table 
of demographics and matching parameters for case and control groups is shown in 
Table 2. 
Discussion  
As the  global burden of diabetes increases, the importance of achieving optimal 
glycemic management to reduce impact on resources, morbidity and mortality, 
becomes a greater priority. (1,12,13,14).  
The concept of monitoring glycemic variability, and its importance in the optimal 
management of patients with diabetes has gained increasing attention. (11) The data 
from this study supports the use of measures of glycemic variability as a means of 
identifying inpatients at elevated risk of long-term increased mortality, and raises the 
potential of targeting glycemic variability with the aim of improving outcome. 
 
Hyperglycaemia is accepted as contributing to increased incidence of the macro and 
microvascular complications of diabetes. In hospital inpatients, multiple 
epidemiological studies in a variety of inpatient settings have demonstrated increased 
mortality associated with hyperglycaemia. These findings led to studies aiming for 
tight glycemic control. (2,3,4,5) 
 
Hypoglycaemia is a major complication of tight glycemic control. (6) The presence of 
hypoglycaemia has been demonstrated to contribute to worse outcomes in hospital 
inpatients. (7,8) Hypoglycaemia in hospital inpatients is associated with increased 
mortality and length of stay. (9,10) This study demonstrated an association between a 
median CBG within the lower 50%, and increased mortality on long term follow up. 
This excess mortality may be a reflection of increased predisposition to 
hypoglycaemia. 
The mechanisms through which hypoglycaemia is associated with mortality are 
complex. The adverse impact of hypoglycaemia on the cardiovascular system may be 
mediated by activation of the sympathetic nervous system and enhanced 
activation/aggregation of thrombocytes. Hypoglycemia has also been associated with 
repolarization abnormalities and increased inflammation which may partially explain 
adverse outcomes.  Cardiovascular disease is the most common cause of death in 
patients with diabetes. It is therefore likely that hypoglycaemia acts as an additional 
risk factor which further adds to the risk to cardiovascular mortality. (7) 
Our data support the hypothesis that there is increased mortality associated with high 
inpatient glycemic variability. This may be explained by negative molecular 
consequences of fluctuations in blood glucose. There is evidence both in vivo and in 
vitro that there are negative biological cellular effects associated with high glycemic 
variability. (18,19,20,21) Harmful oxidative free radicals have been demonstrated to 
be present in high glycemic variability and may contribute to these effects. 
Intermittent glycemic spikes have been shown to enhance apoptosis in cultured 
human cells, more so than consistently high glucose exposure, possibly due to 
overproduction of superoxides in mitochondria. (18,21,22) Several human studies 
have also demonstrated deleterious oxidation products associated with glycemic 
variability. Intermittent high glucose exposure has been shown to be associated with 
both increased levels of oxidative stress markers, and endothelial dysfunction in 
patients with type 2 diabetes. (18,21) In elderly patients with type 2 diabetes, an 
independent association has been shown between increased coefficient of variation of 
fasting plasma glucose, and both all-cause and cardiovascular mortality. In agreement 
with our own data, survival analysis of this study demonstrated that glucose 
variability was detrimental in its own right, regardless of whether overall glycemic 
control was good or poor, as indicated by a high or low mean fasting plasma glucose 
level. (17) A substudy of the Veterans Affairs Diabetes Trial (VADT) has 
demonstrated a link between severe hypoglycaemia and progression of 
atherosclerosis. Although severe hypoglycaemia was seen more commonly in 
intensive glycaemia control patients, severe hypoglycaemia was only associated with 
atherosclerosis progression in the standard therapy arm of the study. This may be 
explained by increased glycemic variability, in that participants in the standard control 
group may have had greater glycemic excursions to reach glucose levels associated 
with severe hypoglycaemia. (23)  
 
Our data demonstrate that long-term mortality is elevated in patients with increased 
glycemic variability. This increased mortality continues on an ongoing basis during 
follow up. It is possible that inpatient variability is a marker for ongoing post 
discharge variability, which may be harmful in itself, or increase potential for 
significant hypoglycaemia. On matching for median blood glucose level, it appears 
that glycemic variability is an independent marker for poorer outcome. However, 
patients with a lower median blood glucose level had a higher mortality than those 
with a higher median blood glucose level, when matched for glycemic variability. 
This may reflect a susceptibility for those with a lower median blood glucose to 
superimposed hypoglycemic excursions and potentially additional associated negative 
effects associated. In this scenario, the possibility of a higher risk of cardiovascular 
mortality may be associated with the cumulative effect of both increased exposure to 
hypoglycaemia, and the negative vascular consequences of high glycemic variability. 
It has recently been demonstrated that in insulin treated diabetes patients, a peri-
operative glucose target of <180 mg/dl may be harmful, whereas in non-insulin 
treated patients, a lower target may confer benefit. (24) It is possible that the higher 
glucose variability seen in insulin treated patients contributes to this observed 
difference. Our data raises questions around the traditional view of targeting tight 
blood glucose control in hospital inpatients. Indeed, our data would suggest that 
patients who achieve a higher median inpatient blood glucose could do better in the 
long-term.  
 
Our data support the potential role of of glycemic variability in determining risk of 
long-term mortality in diabetic inpatients. Reducing glycemic variability is an 
attractive potential approach to attempt to reduce the high mortality in this group. In 
patients in hospital with high glycemic variability, consideration should be given to 
the treatment approaches used with the aim of reducing both inpatient variability, and 
any potentially adverse glycemic profile post discharge. Certain therapeutic options 
may help to reduce glycemic variability. (25) GLP-1 analogues, DPP-4 inhibitors, 
CSII and the new ultraslow insulin analogue degludec, have been shown to reduce 
glycemic variability, and this may confer benefit. (26,27,28). Further study in this 
area would provide more guidance, and would allow clinicians to change patient 
regimens with a view to reducing their glycemic variability. In some clinical settings, 
where high glucose variability exists, aiming for a higher inpatient glycemic target 
range may reduce the risk of harm, by limiting the opportunity for glycemic 
excursions into the hypoglycemic range.  
 
Our study is limited by its retrospective design, and by the absence of other markers 
of illness severity for which we could match within our available data set. It is unclear 
whether inpatient glucose variability reflects later, post discharge, variability in 
glucose - or is simply a surrogate marker for the physiological derangement of severe 
illness. This is an area where further research into the extent to which inpatient 
glycemic variability translates into day to day variability after discharge would be 
useful.  
 
Conclusion  
Our data suggest that high inpatient glycemic variability is independently associated 
with excess mortality, in patients with type 2 diabetes mellitus on long-term 
outpatient follow-up. This may be as a result of the known deleterious effect of 
elevated glycemic variability on the vasculature. For any given level of glycemic 
variability, patients with lower inpatient median glucose levels had increased 
mortality when compared with those with higher median glucose levels. Inpatient 
glycemic targets could aim to reduce glycemic variability, and high inpatient 
variability may be a useful indicator of a high risk of adverse post-discharge glucose 
profiles. In patients with difficult to control high glycemic variability, aiming for 
higher average inpatient blood glucose levels may be appropriate to attempt to 
improve outpatient survival.  
Further research is required to identify whether inpatient variability predicts adverse 
glucose patterns post discharge, and whether an approach that reduces glucose 
variability can reduce morbidity or mortality. 
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Figure 1  
Legend: 6 year survival analysis of individuals with IQR in upper 50% (>=50.9 
mg/dl) (red) vs those with IQR in lower 50% (black). 3165 matched pairs, matched 
for age, duration of diabetes, duration of admission, inpatient median glucose and 
number of episodes of hypoglycaemia. HR for mortality (upper vs lower 50%) 1.17 
(p<0.01). 
 
Table 1 
Legend: Characteristics of case and control groups (IQR analysis). Values given as 
median (IQR) 
 
case control p 
n 3165 3165 - 
n male 1911 1866 0.3 
IQR 3.8 
(3.2-
4.9) 
1.9 
(1.4-
2.4) 
<0.001 
Age 69.8 
(61.0-
76.6) 
69.7 
(61.3-
76.8) 
0.80 
n 
hypoglycemic 
episodes 
386 386 - 
Diabetes 8.2 7.6 0.75 
Duration 
(years) 
(4.5-
12.1) 
(4.2-
11.6) 
Admission 
Duration 
(days) 
3.2 
(1.7-
5.8) 
3.2 
(1.7-
5.8) 
0.81 
Inpatient 
Median 
Glucose 
8.7 
(7.4-
10.2) 
8.7 
(7.4-
10.2) 
0.97 
 
Figure 2 
Legend: 6 year survival analysis of individuals with median CBG in upper 50% 
(>=148.5 mg/dl) (red) vs those with IQR in lower 50% (black). 3755 matched pairs, 
matched for age, duration of diabetes, duration of admission, CBG IQR and number 
of episodes of hypoglycaemia. HR for mortality (upper vs lower 50%) 0.87 
 
Table 2 
Legend: Characteristics of case and control groups (median CBG analysis). Values 
given as median (IQR) 
 
case control p 
n 3755 3755 
 
n male 1652 1617 0.39 
IQR 2.3 
(1.6-
3.0) 
2.3 
(1.6-
3.0) 
0.86 
Age 69.6 
(61.1-
76.9) 
69.7 
(61.1-
77.0) 
0.80 
n 
hypoglycemic 
episodes 
191 191 - 
Diabetes 
Duration 
(years) 
7.5 
(3.8-
11.4) 
7.1 
(3.5-
11.1) 
0.57 
Admission 
Duration 
(days) 
3.2 
(1.6-
5.8) 
3.2 
(1.6-
5.8) 
0.90 
Inpatient 
Median 
Glucose 
9.9 
(8.9-
11.5) 
7.1 
(6.3-
7.7) 
<0.001 
 
